{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:45:32Z","timestamp":1794350732837,"version":"4.9.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"abstract":"<jats:p>G2 and S phase-expressed-1 (GTSE1) has been reported to be associated with poor prognosis in many cancer types. However, the knowledge of GTSE1 across 33 cancer types remains scarce, and the mechanisms by which GTSE1 promotes cancer development remain incompletely understood. R language and TIMER2.0 were used to analyze the clinical relevance of GTSE1 across\u2005&gt;\u200510,000 subjects representing 33 cancer types based on the cancer genome atlas databases. The expression of GTSE1 was upregulated in almost all cancer types and hyperactivity of GTSE1 is likely to induce DNA repair response and positively correlates with the tumor mutational burden and microsatellite instability which are both promising predictive biomarkers for immunotherapy. GTSE1 was upregulated in TP53 mutation patients. Additionally, GTSE1 also positively correlates with tumor purity and tumor infiltration of immune-suppressive myeloid-derived suppressor cells. Consistently, high expression of GTSE1 is associated with poor patient survival in many cancer types. Conclusion: Our study provides new insights into the diagnostic and prognostic role of GTSE1 in cancers and suggests therapeutic approaches for GTSE1-overexpressing cancers by targeting DNA repair response, and the tumor immune microenvironment.<\/jats:p>","DOI":"10.1097\/md.0000000000034996","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T22:01:43Z","timestamp":1693432903000},"page":"e34996","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["Pan-cancer analyses reveal GTSE1 as a biomarker for the immunosuppressive tumor microenvironment"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-8158","authenticated-orcid":false,"given":"Ke","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhen","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, China"},{"name":"Digestive Disease Research Institute, Jiangsu University, Zhenjiang, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41418-022-00996-z","article-title":"Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?","volume":"29","author":"Thomas","year":"2022","journal-title":"Cell Death Differ"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"30356","DOI":"10.1074\/jbc.M302902200","article-title":"The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function.","volume":"278","author":"Monte","year":"2003","journal-title":"J Biol Chem"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"11744","DOI":"10.1074\/jbc.M311123200","article-title":"hGTSE-1 expression stimulates cytoplasmic localization of p53.","volume":"279","author":"Monte","year":"2004","journal-title":"J Biol Chem"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1093\/emboj\/17.17.5015","article-title":"A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression.","volume":"17","author":"Utrera","year":"1998","journal-title":"EMBO J"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1550-0","article-title":"GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells.","volume":"15","author":"Subhash","year":"2015","journal-title":"BMC Cancer"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41374-020-00510-4","article-title":"GTSE1 promotes prostate cancer cell proliferation via the SP1\/FOXM1 signaling pathway.","volume":"101","author":"Lai","year":"2021","journal-title":"Lab Investig"},{"key":"R7-20250504","first-page":"1","article-title":"GTSE1 is involved in breast cancer progression in p53 mutation-dependent manner.","volume":"38","author":"Lin","year":"2019","journal-title":"Jour Exp Clin Cancer Res"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ijbiomac.2018.11.032","article-title":"Overexpression of G2 and S phase-expressed-1 contributes to cell proliferation, migration, and invasion via regulating p53\/FoxM1\/CCNB1 pathway and predicts poor prognosis in bladder cancer.","volume":"123","author":"Liu","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"R9-20250504","first-page":"1","article-title":"GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis.","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data.","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat Commun"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2. 0 for analysis of tumor-infiltrating immune cells.","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells.","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13059-016-1028-7","article-title":"Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.","volume":"17","author":"Li","year":"2016","journal-title":"Genome Biol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-021-04021-x","article-title":"CHARTS: a web application for characterizing and comparing tumor subpopulations in publicly available single-cell RNA-seq data sets.","volume":"22","author":"Bernstein","year":"2021","journal-title":"BMC Bioinf"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"D900","DOI":"10.1093\/nar\/gky939","article-title":"CancerSEA: a cancer single-cell state atlas.","volume":"47","author":"Yuan","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cell.2020.05.039","article-title":"Multimodal analysis of composition and spatial architecture in human squamous cell carcinoma.","volume":"182","author":"Ji","year":"2020","journal-title":"Cell"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7150\/jca.48983","article-title":"LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma.","volume":"12","author":"Wang","year":"2021","journal-title":"J Cancer"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejca.2020.02.038","article-title":"Tumour mutational burden as a biomarker for immunotherapy: current data and emerging concepts.","volume":"131","author":"Fumet","year":"2020","journal-title":"Eur J Cancer"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition.","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer.","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential.","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nature Rev Gastroenterol Hepatol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cub.2009.09.055","article-title":"Deviant kinetochore microtubule dynamics underlie chromosomal instability.","volume":"19","author":"Bakhoum","year":"2009","journal-title":"Curr Biol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1083\/jcb.201606081","article-title":"GTSE1 tunes microtubule stability for chromosome alignment and segregation by inhibiting the microtubule depolymerase MCAK.","volume":"215","author":"Bendre","year":"2016","journal-title":"J Cell Biol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","article-title":"The cytosolic DNA-sensing cGAS\u2013STING pathway in cancer.","volume":"10","author":"Kwon","year":"2020","journal-title":"Cancer Discov"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.abg5784","article-title":"The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.","volume":"373","author":"Martin","year":"2021","journal-title":"Science"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","article-title":"Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.","volume":"7","author":"Palmeri","year":"2022","journal-title":"ESMO Open"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid Tumors FDA approval summary: pembrolizumab for MSI-H Solid Tumors.","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/vaccines4040036","article-title":"The role of myeloid-derived suppressor cells (MDSC) in cancer progression.","volume":"4","author":"Umansky","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"e1196312","DOI":"10.1080\/2162402X.2016.1196312","article-title":"Improving cancer immunotherapy by targeting the STATe of MDSCs.","volume":"5","author":"de Haas","year":"2016","journal-title":"Oncoimmunology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034996","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:03:06Z","timestamp":1746327786000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":30,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034996","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}